Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: A quantitative rat model of immune thrombocytopenic purpura

Journal of Pharmacology and Experimental Therapeutics

Volumn 298, Issue 1, 2001, Pages 165-171

  Hansen, Ryan J ^a   Balthasar, Joseph P ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST;

ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BLEEDING; BLOOD VOLUME; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS REACTION; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HALF LIFE TIME; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RAT; REPRODUCIBILITY; STEADY STATE; THROMBOCYTE COUNT;

ANIMALS; ANTIBODIES, MONOCLONAL; BLEEDING TIME; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; MICE, INBRED BALB C; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RATS; RATS, SPRAGUE-DAWLEY; TUMOR CELLS, CULTURED;

EID: 0034977201     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Erythrocytes with covalently bound fibrinogen as a cellular replacement for the treatment of thrombocytopenia
2. Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model
3. Protective effect of pantethine on experimental thrombocytopenia in the rat
4. Defect of platelet aggregation and adhesion induced by autoantibodies against platelet glycoprotein IIIa
5. Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab′)2 and Fab after intravenous administration in the rat
6. Sustained antiplatelet properties of nitroglycerin during hemodynamic tolerance in rats
7. Kinetics of W3/25 anti-rat CD4 monoclonal antibody. Studies on optimal doses and time-related effects
8. Mean residence time concepts for pharmacokinetic systems with nonlinear drug elimination described by the Michaelis-Menten equation
9. A comparative analysis of cDNA-derived sequences for rat and mouse beta 3 integrins (GPIIIA) with their human counterpart
10. The effect of monoclonal anti-human-platelet antibodies on platelet kinetics in a baboon model: IgG subclass dependency
11. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex
12. Autoantibodies to the presumptive cytoplasmic domain of platelet glycoprotein IIIa in patients with chronic immune thrombocytopenic purpura
13. Platelet activation in whole blood by artificial surfaces: Identification of platelet-derived microparticles and activated platelet binding to leukocytes as material-induced activation events
14. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology
15. An ELISA for quantification of murine IgG in rat plasma: Application to the pharmacokinetic characterization of AP-3, a murine anti-glycoprotein IIIa monoclonal antibody, in the rat
16. Kinetics of platelets in dogs with thrombocytopenia induced by antiglycoprotein IIb/IIIa receptor monoclonal antibody
17. Immunoglobulins targeting both GPIIb/IIIa and GPIb/IX in chronic idiopathic thrombocytopenic purpura (ITP): Evidence for at least two different IgG antibodies
18. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit
19. Bleeding times and the antithrombotic effects of high-dose aspirin, hirudin and heparins in the rat
20. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
21. Therapy for adults with refractory chronic immune thrombocytopenic purpura
22. Biochemical pharmacology of platelet-activating factor (and PAF antagonists) in relation to clinical and experimental thrombocytopenia
23. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice
24. (NZW x BXSB)F1 mouse. A new animal model of idiopathic thrombocytopenic purpura
25. Platelet antibody testing in idiopathic thrombocytopenic purpura
26. A liposome based platelet substitute, the plateletsome, with hemostatic efficacy
27. Molecular basis of pharmacologic selectivity
28. Pharmacokinetics and metabolism of therapeutic and diagnostic antibodies
29. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets